“Knowing upfront which parts of a clinical study are primed to have digital interventions or decentralized replacements is key to moving faster with less burden on sites and patients. These insights also help teams invest in the right combinations of emerging technologies
and channels.”
Mike Martin
ZS’s global clinical development leader
“Right now, the focus across supply chain and manufacturing is ensuring that products reach patients. The digitalization will avoid stock-outs and enable patient access to drugs. This will also enable getting ready to manufacture more complex products, including CAR-T and mRNA therapies. Autonomous and continuous manufacturing will help them with the complexity and speed needed for those, all while they do more with less—less waste, less footprint and less cost.”
Anshul Agarwal
ZS’s global supply chain and manufacturing leader
“We find many companies are still far too conservative in their ambitions for healthcare provider personalization. We’ve scaled next best action across 15 countries for nine brands in under 18 months. With the right leadership support, commitment and use of right platforms, companies can scale personalized next best actions across brands very, very quickly.”
Omer Hancer
ZS’s global customer experience AI and analytics leader
